The Trump administration has banned federal funding for fentanyl test strips and other drug-testing kits, marking what officials call a decisive break from harm reduction policy. The Substance Abuse and Mental Health Services Administration issued guidance in April prohibiting the use of its grants to purchase or distribute the strips, which detect fentanyl, xylazine, and medetomidine.
The agency claimed the strips facilitate illicit drug use and violate federal law. But harm reduction advocates say the move will have catastrophic consequences for people struggling with addiction facing an increasingly lethal drug supply.
Maia Szalavitz, a New York Times columnist and author of a book on harm reduction, was blunt: "It's going to kill people." She criticized HHS Secretary Robert F. Kennedy Jr. for what she characterized as an extremist abstinence-only ideology that ignores decades of public health evidence.
The policy reversal stunned the field. Under the Biden administration, federal funding for test strips became available in 2021 as a tool to prevent overdose deaths from fentanyl contamination. When that permission came through, sales at DanceSafe, a leading nonprofit distributor, quintupled almost immediately. Test strips cost less than a dollar and have been credited with helping people make informed decisions about their drug use.
Daniel Fishbein, policy manager for the Drug Policy Alliance, said the new guidance contradicts both congressional intent and research. "What we keep hearing from the administration is that they believe that fentanyl test strips promote drug use," he said. "Based on the research that I've reviewed, that's simply not the case."
The contradiction runs deeper. The White House's National Drug Control Strategy, published last week, explicitly states that test strips "are an important tool that should be legal." The conflicting messages suggest tensions within the administration over drug policy direction.
The impact is already visible on the ground. Several states have paused fentanyl test strip distribution programs to comply with the new federal guidance. The Kentucky Harm Reduction Coalition, which distributed nearly 50,000 strips in the first three months of this year, faces the loss of a $400,000 federal grant and has only about a month's supply remaining.
Emanuel Sferios, founder of Grassroots Harm Reduction, described the administration's move as an assault on the core principle that people will use drugs regardless of prohibition, and that public health should focus on keeping them as safe as possible. "In those small places where you can still find heroin, these are absolutely lifesaving strips," he said.
The crackdown extends beyond test strips. Samhsa also barred federal funding for overdose hotlines and safer drug-consumption facilities, which first appeared in New York City in 2021 and reversed more than 1,000 overdoses within two years. An executive order signed by Trump last year already banned federal support for such facilities.
Congress appeared to reject this ideological stance. In December, lawmakers passed the Support for Patients and Communities Reauthorization Act, which Trump signed, explicitly authorizing the use of federal opioid response grants to facilitate access to fentanyl and xylazine test strips. Fishbein called the new Samhsa guidance "a violation of congressional intent."
The context matters. Nearly 80,000 Americans die from overdoses annually. The Biden administration's support for harm reduction measures, including test strips and medication-assisted treatment, contributed to a 26 percent decline in overdose deaths from 2023 to 2024. Yet since Trump took office, Samhsa has cut $350 million in addiction and overdose prevention funding.
The street drug supply has become more treacherous and unpredictable. Fentanyl, a synthetic opioid thousands of times stronger than heroin, is now mixed into countless street drugs by dealers seeking to increase potency. More recently, xylazine, a sedative that causes severe withdrawal symptoms, has contaminated supplies. Now medetomidine, another potent sedative with excruciating withdrawal that can trigger heart attacks, is spreading. Test strips offer a crucial way to detect these adulterants before consumption.
The HHS has characterized the restrictions as part of an effort to direct taxpayer money toward "effective, commonsense solutions that have been proven to keep people out of an endless cycle of addiction and save lives." A spokesperson emphasized the expansion of access to naloxone, an overdose reversal medication.
In a sign of internal inconsistency, Trump has also issued recent executive orders to accelerate research into psychedelic therapies and remove cannabis from the strictest category of controlled substances, moves that surprised drug reform advocates.
Author James Rodriguez: "The administration's war on test strips is ideological theater masquerading as drug policy, and it will cost lives while Congress watches from the sidelines."
Comments